title: Anti-hypertensive drugs have different effects on ventricular hypertrophy regression.
abstract: OBJECTIVE
  There is a direct relationship between the regression of left ventricular hypertrophy (LVH) and a decreased risk of mortality. This investigation aimed to describe the effects of anti-hypertensive drugs on cardiac hypertrophy through a meta-analysis of the literature.
  
  
  METHODS
  The Medline (via PubMed), Lilacs and Scielo databases were searched using the subject keywords cardiac hypertrophy, antihypertensive and mortality. We aimed to analyze the effect of anti-hypertensive drugs on ventricle hypertrophy.
  
  
  RESULTS
  The main drugs we described were enalapril, verapamil, nifedipine, indapamina, losartan, angiotensin-converting enzyme inhibitors and atenolol. These drugs are usually used in follow up programs, however, the studies we investigated used different protocols. Enalapril (angiotensin-converting enzyme inhibitor) and verapamil (Ca(++) channel blocker) caused hypertrophy to regress in LVH rats. The effects of enalapril and nifedipine (Ca(++) channel blocker) were similar. Indapamina (diuretic) had a stronger effect than enalapril, and losartan (angiotensin II receptor type 1 (AT1) receptor antagonist) produced better results than atenolol (selective beta1 receptor antagonist) with respect to LVH regression.
  
  
  CONCLUSIONS
  The anti-hypertensive drugs induced various degrees of hypertrophic regression.
authors.affiliation: Departamento de Clínica Médica, Faculdade de Medicina do ABC, Santo André/SP, Brasil. celsoferreira.dmed@epm.br
authors.forename: Celso
authors.initials: C
authors.lastname: Ferreira Filho
authors.forename: Luiz Carlos de
authors.initials: LC
authors.lastname: Abreu
authors.forename: Vitor E
authors.initials: VE
authors.lastname: Valenti
authors.forename: Marcelo
authors.initials: M
authors.lastname: Ferreira
authors.forename: Adriano
authors.initials: A
authors.lastname: Meneghini
authors.forename: José Alexandre
authors.initials: JA
authors.lastname: Silveira
authors.forename: Andrés R Pérez
authors.initials: AR
authors.lastname: Riera
authors.forename: Eduardo
authors.initials: E
authors.lastname: Colombari
authors.forename: Neif
authors.initials: N
authors.lastname: Murad
authors.forename: Paulo Roberto
authors.initials: PR
authors.lastname: Santos-Silva
authors.forename: Lovian José Henrique Pereira da
authors.initials: LJ
authors.lastname: Silva
authors.forename: Luiz Carlos Marques
authors.initials: LC
authors.lastname: Vanderlei
authors.forename: Tatiana D
authors.initials: TD
authors.lastname: Carvalho
authors.forename: Celso
authors.initials: C
authors.lastname: Ferreira
mesh_terms: D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000517:prevention & control; D017379:Hypertrophy, Left Ventricular / Q000188:drug therapy* / Q000401:mortality; D051381:Rats; D012074:Remission Induction / Q000379:methods; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents